Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies.

Ingrid Glimelius^1,2, Love Tätting³, Jonatan Freilich^4,5, M Natalia Stelmaszuk⁴, Qian Yang⁶, Anna Deleskog⁷, Sigurður Y Kristinsson⁸

¹Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Uppsala University Uppsala Sweden.

²Blood Oncology and Tumour Disease Oncology Clinic Akademiska University Hospital Uppsala Sweden.

³Department of Haematology in Linköping and Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden.

⁴Access Consulting - RWE Parexel International Stockholm Sweden.

⁵Department of Public Health and Clinical Medicine Umeå University Umeå Sweden.

⁶RWE Consulting - Epidemiology & COA Parexel International Stockholm Sweden.

⁷Takeda Pharma AB Stockholm Sweden.

⁸Faculty of Medicine University of Iceland Reykjavik Iceland.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection-related mortality remains a significant concern for patients' overall survival (OS). METHODS: This Swedish, population-based study examined incidence of infections and OS in patients with MM or CLL between January 2010 and De…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.